EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Zivo Bioscience's Enterprise Value is $62.99 Mil.
Zivo Bioscience's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was $-4.31 Mil. Therefore, Zivo Bioscience's EV-to-FCF for today is -14.60.
The historical rank and industry rank for Zivo Bioscience's EV-to-FCF or its related term are showing as below:
ZIVO'
s EV-to-FCF Range Over the Past 10 Years
Min: -30.15 Med: -8.94 Max: -0.2
Current: -15.12
During the past 13 years, the highest EV-to-FCF of Zivo Bioscience was -0.20. The lowest was -30.15. And the median was -8.94.
ZIVO's EV-to-FCF is ranked worse than 100% of 424
companies
in the Biotechnology industry
Industry Median: 3.285
vs ZIVO: -15.12
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
The historical data trend for Zivo Bioscience's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Zivo Bioscience's EV-to-FCF
For the Biotechnology subindustry, Zivo Bioscience's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zivo Bioscience's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zivo Bioscience's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Zivo Bioscience's EV-to-FCF falls into.
Zivo Bioscience's current Enterprise Value is $62.99 Mil.
Zivo Bioscience's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.31 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Zivo Bioscience's PE Ratio (TTM) for today is calculated as:
Zivo Bioscience's share price for today is $17.10.
Zivo Bioscience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.280.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Zivo Bioscience EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Zivo Bioscience's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Zivo Bioscience Inc is a research and development company operating in both the biotech and agtech sectors, with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. The company's candidates are Bovine Mastitis, Canine Joint Health, Human Immune Modulation, Companion Animal Food Ingredient, NDI (New Dietary Ingredient, and Skin Health.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ZIVO has been successfully added to your 